Creative Biolabs Launches Advanced Antibody Tools for Neuroscience Research
Creative Biolabs has developed specialized antibody products targeting key neurological proteins that could accelerate research into neurodegenerative diseases, movement disorders, and synaptic function.
Creative Biolabs has introduced a comprehensive suite of antibody tools targeting critical neuroscience proteins, including GRID2, tyrosine hydroxylase, and ACTN3, providing researchers with advanced resources to study neurological diseases and synaptic function. The development comes as the global burden of neurodegenerative diseases, movement disorders, and psychiatric disorders continues to escalate, driving urgent need for better research tools and treatment options.
The company's anti-GRID2 antibody products, including Rabbit Anti-GRID2 Recombinant Antibody and Mouse Anti-GRID2 Recombinant Antibody, represent a significant advancement for studying cerebellar ataxia and learning deficits. Research has demonstrated that GRID2 gene mutations can lead to these conditions, with the protein playing a dominant role in motor coordination and synaptic transmission. These antibody tools are applicable in multiple research methods including ELISA, flow cytometry, Western blotting, and immunohistochemistry, allowing researchers to accurately study spatial characteristics and dynamic regulation of synaptic proteins. A neuroscientist at Creative Biolabs explained that GRID2 has emerged as a key point for understanding both cerebellar development and mechanism learning, with the antibody tool sets designed to assist researchers in generating clearer molecular maps within cell and animal model systems.
For neurotransmitter research, Creative Biolabs offers the Mouse Anti-Tyrosine Hydroxylase Recombinant Antibody (AV1), targeting the rate-limiting enzyme in catecholamine synthesis. Tyrosine hydroxylase catalyzes the conversion of L-tyrosine to L-DOPA, which subsequently produces dopamine, norepinephrine, and epinephrine. This makes TH particularly important in Parkinson's disease research, where changes in TH levels reflect the functional state of dopaminergic neurons. The antibody is optimized for Western blot and immunohistochemistry applications, helping researchers sensitively capture molecular changes along neurotransmitter synthesis pathways. The company emphasized that TH research is critical not only for understanding underlying mechanisms related to Parkinson's disease but also for developing new neuroprotective strategies.
Beyond neural-specific targets, Creative Biolabs has developed ACTN3-related products including Mouse Anti-ACTN3 Recombinant Antibody and Rabbit Anti-ACTN3 Recombinant Antibody. The ACTN3 gene encodes α-actinin-3, a critical protein for maintaining structural integrity and explosive power of fast-twitch muscle fibers. These tools support studies in sports genetics, muscle disorders, and personalized training research, with applications spanning immunohistochemistry, Western blotting, immunocytochemistry, and flow cytometry. The products feature high specificity and cross-species applications, addressing growing interest in genetic regulation within the motor system.
The availability of these specialized antibody tools at https://www.creative-biolabs.com could accelerate research across multiple neurological domains by providing researchers with precise molecular probes for studying disease mechanisms. As neurological disorders continue to represent a significant global health challenge, these research tools may contribute to faster identification of therapeutic targets and improved understanding of complex neurological pathways.